Ecuador, Egypt, Estonia, India, Kazakhstan, Lebanon, Latvia, Lithuania, Macedonia, Malta, Nepal, Philippines, Peru, Russia, Romania, Serbia, Slovenia, Slovakia, South Africa, Turkey and Uruguay.
Following intense discussion covering a number of concerns, the CML patient organizations worked towards concluding the meeting with a declaration that calls for quality and consistency when generics and copies of patented drugs are introduced on the market. In the face of more generic formulations entering the market, the group felt clearer guidance is required for demonstration of bioequivalence to the originator product, especially for drugs with a narrow therapeutic range. 2, 4 In some countries, generic formulations can be authorized on the basis of in vitro dissolution tests without clinical evidence of bioequivalence. 7, 10 There have been reports of loss of efficacy after switching to generic formulations. 6 The group supported the suggestion that manufacturers of generic formulations should not only demonstrate clinical bioequivalence but also provide comparative clinical data with appropriate treatment group sample sizes following generic drug approval. 5 Patients welcomed and acknowledged that generics may improve patient access to more affordable therapies in many countries. 9 However, patients also raised concerns about being switched between different products for non-medical reasons. Notably, what impact would alternative, less expensive products have on the management of CML when the quality, safety and efficacy of these alternative products in patients is uncertain? 5, 6, 8, 11 CML patient groups called out to governments, health authorities and healthcare professionals to minimize the potential uncertainties and risks for patients with the following five recommendations:
1. No generic drug to treat CML should be provided to patients without reliable proof of quality as well as bioequivalence (equivalent bioavailability/pharmacokinetics) to the originator drug. Generic drugs should be approved by the appropriate authorities of the respective country or region, and a narrow therapeutic range of some cancer drugs should be considered before acceptance of bioequivalence. 2. When generic drugs are intended for the treatment of severe diseases like leukemia, further comparative clinical data should be demanded by regulatory bodies and published to ensure that the generic drug is therapeutically equivalent (same safety and efficacy) to the original product in patients. 3. A CML patient should not be switched between different products with the same active substance for non-medical reasons provided this patient already responded optimally to the current product and tolerates it well. 4. If a switch for non-medical reasons between products with the same active substance is enforced, this should not happen more frequently than once a year. Sufficient follow-up is necessary to assess safety and efficacy to estimate drug response. If a patient experiences loss of drug response or experiences a significant increase in toxicity after switching to another product containing the same active substance, the patient must have the option to return to the previous treatment or switch to another treatment, if available.
5. After switching between products with the same active substance, more frequent molecular monitoring should be conducted to detect potential differences in effectiveness or side effects early after the switch.
There is significant uncertainty for both prescribers and patients concerning the introduction of generic formulations of CML TKIs. More data and guidance are necessary when patients are being switched to alternative, less expensive products, to ensure the procedures are equally safe and that the risk of increased toxicity and/or loss of drug response is minimized. The recommendations from the patient community may provide a basis for discussion by the expert groups for publishing treatment guidelines and recommendations for the management of CML. Previous guidelines such as the European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 (ref. 12) serve as a valuable reference source for patients and physicians seeking to reduce the level of risk and uncertainty for safe administration of generic formulations of CML TKIs.
